youtube_live
Q3 2026 earnings • released • EPS miss -63.62% • Revenue beat +8.93%
See resultschevron_right
SRPT:NASDAQ
Sarepta Therapeutics Inc
$17.82
arrow_upward
+1.42%(+0.25) 1D
$17.82
0.00% (0.00)
bedtimeAfter hours
Closed: Nov 6, 4:00:00 PM GMT-5 · USD
search
All symbols
No data
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SRPT...
Open
$18.77
High
$18.77
Low
$17.52
Mkt. cap
1.88B
Avg. vol.
2.49M
Volume
2.60M
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.45
Shares outstanding
105.63M
No. of employees
835
Open
$18.77
High
$18.77
Low
$17.52
Mkt. cap
1.88B
Avg. vol.
2.49M
Volume
2.60M
52-wk high
$24.68
52-wk low
$14.68
EPS
-$1.66
Beta
0.45
Shares outstanding
105.63M
No. of employees
835
News stories
From web sources and news partners
Yahoo Finance Singapore
·
6 hours ago
Learn Why The Bull Case For Sarepta Therapeutics Stock Could Change Following Raised Revenue Guidance
BioSpace
·
23 hours ago
Sarepta’s new CEO confident in clinical execution as DMD competitors close in
The Globe and Mail
·
1 day ago
Sarepta (SRPT) Q3 2026 Earnings Call Transcript
Profile
Sarepta Therapeutics, Inc. is a medical research and drug development company with corporate offices and research facilities in Cambridge, Massachusetts, United States. Incorporated in 1980 as AntiVirals, shortly before going public the company changed its name from AntiVirals to AVI BioPharma soon with stock symbol AVII and in July 2012 changed name from AVI BioPharma to Sarepta Therapeutics and SRPT respectively. As of 2023, the company has four approved drugs. Wikipedia
About Sarepta Therapeutics Inc
CEODouglas S. Ingram
Employees835
Founded1980
Headquarters-
SectorHealth Care
IndustryBiotechnology
Websitesarepta.com
Analyst ratings
Based on 16 analysts giving stock ratings to SRPT in the past 3 months
Hold
Buy
3
Hold
9
Sell
4
12-month forecast
Based on 16 Wall Street analysts offering 12 month price targets for SRPT in the last 3 months.
Highest
Current $17.82
$38.00 (+113.24%)
Average
$21.77 (+22.17%)
Lowest
$5.00 (-71.94%)
Analyst | Recommendation | Action | Price target | Projected | Date |
|---|---|---|---|---|---|
Tazeen Ahmad Bank of America Securities | Sell | Maintained | - | - | 11/06/2026 |
Michael Ulz Morgan Stanley | Hold | Reiterated | $25.00 | +40.3% | 11/06/2026 |
Kostas Biliouris Oppenheimer | Buy | Maintained | $35.00 | +96.4% | 11/06/2026 |
Yanan Zhu Wells Fargo | Buy | Maintained | $38.00 | +113.2% | 11/06/2026 |
Yun Zhong Wedbush | Buy | Reiterated | $35.00 | +96.4% | 11/06/2026 |
Brian Abrahams RBC Capital | Hold | Maintained | $18.00 | +1% | 11/05/2026 |
Biren Amin Piper Sandler | Hold | Maintained | $20.00 | +12.2% | 11/06/2026 |
Mitchell Kapoor H.C. Wainwright | Sell | Reiterated | $5.00 | -71.9% | 11/06/2026 |
Brian Skorney Robert W. Baird | Hold | Maintained | $18.00 | +1% | 11/06/2026 |
Ritu Baral TD Cowen | Hold | Maintained | $17.00 | -4.6% | 10/21/2026 |
Unknown Analyst Leerink Partners | Hold | Reiterated | $20.00 | +12.2% | 10/15/2026 |
Anupam Rama J.P. Morgan | Hold | Reiterated | $20.00 | +12.2% | 09/30/2026 |
Lachlan Hanbury Brown William Blair | Hold | Reiterated | - | - | 09/28/2026 |
Gil Blum Needham | Sell | Maintained | - | - | 09/28/2026 |
Yigal Nochomovitz Citi | Sell | Maintained | $13.00 | -27% | 09/27/2026 |
Gavin Clark-Gartner Evercore ISI | Hold | Maintained | $19.00 | +6.6% | 08/10/2026 |
Eliana Merle Barclays | Hold | Maintained | $20.00 | +12.2% | 08/07/2026 |
Kristen Kluska Cantor Fitzgerald | Hold | Maintained | $21.00 | +17.8% | 08/05/2026 |
Uy Ear Mizuho Securities | Buy | Maintained | $31.00 | +74% | 07/10/2026 |
Andy Chen Wolfe Research | Buy | Upgraded | $27.00 | +51.5% | 07/08/2026 |
Stephen Brozak WBB Securities | Buy | Maintained | $38.00 | +113.2% | 03/26/2026 |
Unknown Analyst WBB Securities | Buy | Maintained | $38.00 | +113.2% | 03/26/2026 |
David Hoang Deutsche Bank | Sell | Maintained | $14.00 | -21.4% | 03/26/2026 |
William Pickering Bernstein | Hold | Maintained | $20.00 | +12.2% | 03/25/2026 |
Joseph Schwartz Leerink Partners | Hold | Maintained | $15.00 | -15.8% | 03/25/2026 |
Unknown Analyst Guggenheim | Buy | Reiterated | $19.00 | +6.6% | 03/09/2026 |
Salveen Richter Goldman Sachs | Hold | Maintained | $17.00 | -4.6% | 02/25/2026 |
Sami Corwin William Blair | Hold | Reiterated | - | - | 02/26/2026 |
Last report
Nov 5, 2026
Fiscal period
Q3 2026
- Normalized EPS / Est. (USD)
- GAAP EPS / Est. (USD)
$0.13 / $0.36
-63.62%miss
arrow_downward
Revenue / Est. (USD)
381.35M / 350.10M
+8.93%beat
arrow_upward
Fiscal Q3 2026 earnings call
youtube_liveWaiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
- Quarterly
- Annual
All values in USD | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 |
|---|---|---|---|---|
Revenue | 399.36M | 442.93M | 730.80M | 401.25M |
Cost of goods sold | 369.66M | 724.04M | 262.73M | 240.64M |
Cost of revenue | 369.66M | 724.04M | 262.73M | 240.64M |
Research and development expenses | - | - | - | - |
Total research and development expenses | - | - | - | - |
Selling, general, and admin expenses | 91.89M | 128.30M | 108.95M | 107.60M |
Operating expense | 92.57M | 128.97M | 109.64M | 108.32M |
Total operating expenses | 462.24M | 853.02M | 372.37M | 348.96M |
Operating income | -62.88M | -410.08M | 358.43M | 52.29M |
Other non operating income | -702.00K | -338.00K | 1.16M | -246.00K |
EBT including unusual items | -194.05M | -278.30M | 343.17M | -1.75M |
EBT excluding unusual items | -63.90M | -423.20M | 344.24M | 36.74M |
Income tax expense | -14.10M | 4.55M | 12.22M | 3.14M |
Effective tax rate | 7.27% | -1.64% | 3.56% | -179.59% |
Other operating expenses | - | - | - | - |
Net income | -179.95M | -282.85M | 330.96M | -4.89M |
Net profit margin | -45.06% | -63.86% | 45.29% | -1.22% |
Earnings per share | -0.13 | -3.58 | 3.16 | 0.64 |
Interest and investment income | 7.25M | 8.07M | 6.36M | 6.21M |
Interest expense | -7.56M | -20.84M | -21.71M | -21.51M |
Net interest expenses | -316.00K | -12.77M | -15.35M | -15.30M |
Depreciation and amortization charges | - | - | - | - |
EBITDA | -44.43M | -404.83M | 369.03M | 62.70M |
Gain or loss from assets sale | - | - | - | - |
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider | Position | Type | Date | Shares | Amount |
|---|---|---|---|---|---|
Page 1
Upcoming events